Obakulactone: A Natural Ally Against Inflammatory Arthritis

A recent investigation, documented in the journal Engineering, indicates that obakulactone (OL), a naturally occurring tetracyclic triterpenoid derived from Phellodendri cortex, demonstrates a therapeutic potential for rheumatoid arthritis (RA). This efficacy is attributed to its ability to foster the breakdown of acyl coenzyme A thioesterase 1 (ACOT1) through the ubiquitin‒proteasome degradation pathway, thereby re-establishing equilibrium in unsaturated fatty acid levels. The findings illuminate the precise molecular mechanisms by which OL intervenes in RA and introduce ACOT1 as a novel therapeutic target for this condition. Furthermore, the research presents a fresh perspective on leveraging the reprogramming of fatty acid metabolism as a viable treatment strategy for RA.

Within the scope of this research, scientists developed a rat model of RA induced by complete Freund’s adjuvant (CFA). These RA-afflicted rats were subsequently administered OL in varying concentrations—low (50 mg·kg⁻¹·d⁻¹), medium (100 mg·kg⁻¹·d⁻¹), and high (200 mg·kg⁻¹·d⁻¹)—over a period of 21 days. The outcomes revealed that OL significantly mitigated joint edemas in the RA rats. Additionally, it restored the typical architecture of cartilage and synovial tissues and improved pathological manifestations in immune organs, specifically the thymus and spleen. The administration of OL also served to suppress the elevated presence of CD3⁺ T cells and CD68⁺ macrophages within the joint tissues. A notable shift in macrophage polarization was observed, moving from a pro-inflammatory M1 phenotype (marked by CD86) towards an anti-inflammatory M2 dominant state (characterized by CD206). Moreover, OL inhibited the differentiation of CD4⁺ T cells into Th17 cells. Beyond these cellular effects, OL demonstrably reduced, in a dose-dependent manner, the serum concentrations of pro-inflammatory cytokines like IL-1β, IL-6, IL-17, and TNF-α. It also lowered levels of RA diagnostic markers such as RF, CCP-Ab, CRP, and MMP-3 in the treated rats.

Employing multiomics approaches, encompassing metabolomics, MALDI mass spectrometry imaging, and proteomics, the study demonstrated that OL effectively rectified the aberrant biosynthesis and metabolic pathways of unsaturated fatty acids (including arachidonic acid, linoleic acid, and α-linolenic acid) in the RA rat cohort. In vitro investigations corroborated these findings, showing that OL impeded the proliferation of RA synovial fibroblasts (SFs), induced apoptosis in these cells, and diminished the release of inflammatory cytokines. At the molecular level, cellular thermal shift assays, microscale thermophoresis, and surface plasmon resonance experiments confirmed ACOT1 as the direct molecular target of OL. The dissociation constant (K_d) was determined to be (6.18 ± 0.26) μmol·L⁻¹ via microscale thermophoresis (MST) and (6.34 ± 0.38) μmol·L⁻¹ via surface plasmon resonance (SPR). OL was found to accelerate the ubiquitination-mediated degradation of ACOT1 by the proteasome, consequently decreasing the expression of stearoyl-CoA desaturase-1 (SCD1), a downstream effector. This process, in turn, inhibited the activation of the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) and phosphoinositide 3-kinase (PI3K)–protein kinase B (AKT) signaling cascades. Ultimately, these combined effects led to the suppression of inflammation and fibrosis in SFs. Further supplementary experiments, including rescue assays and the use of specific inhibitors, substantiated that OL exerts its anti-inflammatory, anti-proliferative, and pro-apoptotic actions by engaging with ACOT1 to modulate the arachidonic acid pathway and the downstream JAK–STAT/PI3K–AKT signaling networks.

Rheumatoid arthritis (RA) is recognized as a chronic, systemic autoimmune condition affecting approximately 1% of the global population. Current therapeutic interventions often exhibit limited effectiveness and are associated with significant adverse side effects. This present study furnishes empirical validation for OL as a promising therapeutic agent for RA and underscores the critical role of targeting ACOT1 and regulating unsaturated fatty acid metabolism in the management of RA. These discoveries pave the way for the advancement of novel pharmaceutical agents designed to combat RA.